Emile Nuwaysir, PhD

Board Member

Dr. Emile Nuwaysir is an accomplished biotechnology executive and board leader with a track record of building and scaling transformative companies in regenerative medicine and cell and gene therapy. He currently serves as the CEO of Stylus Medicine. He previously served as the CEO and Chairman of BlueRock Therapeutics, where he led the company from inception to the development of a first-in-class cell therapy for Parkinson’s disease and its acquisition by Bayer Pharmaceuticals. He is the prior Chairman of the Alliance for Regenerative Medicine, representing over 400 global organizations in the cell and gene therapy sector. Earlier in his career, Dr. Nuwaysir was President and COO of Cellular Dynamics International (CDI), where he guided the company through its IPO and subsequent acquisition by Fujifilm. Dr. Nuwaysir holds a PhD in molecular toxicology from the University of Wisconsin–Madison, with postdoctoral fellowships at the NIH and the University of North Carolina at Chapel Hill. His career reflects a consistent focus on translating advanced science into clinical impact through strategic leadership and innovation.